The U.S. Centers for Disease Control and Prevention (CDC) cited recent data on Tuesday (14th) showing that Modena’s vaccine may have a higher risk of heart inflammation in a certain age group than Pfizer’s BNT’s new crown vaccine.
According to the CDC, the risk of myocarditis and pericarditis following administration of vaccines developed with mRNA technology is inconsistent across all vaccine safety monitoring systems in the United States.
The CDC study comes as U.S. Food and Drug Administration (FDA) advisers meet to discuss whether to approve the Moderna vaccine for children ages 6-17.
According to the Vaccine Safety Datalink system, the incidence of myocarditis in men aged 18 to 39 years following a second dose of the Moderna vaccine was 97.3 cases per million doses, compared with the Pfizer/BioNTech vaccine There were 81.7 cases per million doses.
However, the CDC said existing information suggests that most people who develop myocarditis following receiving the mRNA vaccine will recover over time.
According to the Vaccine Safety Datalink system, the incidence of heart inflammation in men aged 18 to 39 following a second dose of Moderna vaccine was 97.3 cases per 1 million doses, while Pfizer BNT The vaccine was 81.7 per 1 million doses.
The CDC said that there is current information that most people who develop myocarditis following the mRNA vaccine will recover over time.
Before the deadline, Modena (MRNA-US) shares were not affected by the news in early trading, rising 2.21% to $119.72 per share; Pfizer (PFE-US) slightly up 0.16%, at $48 per share, BioNTech (BNTX-US) rose 2.17% to $136.52 per share.
